论文部分内容阅读
伊维菌素 (Ｉｖｅｒｍｅｃｔｉｎ)是我国研制的二类新药 ,国外已大规模应用治疗盘尾丝虫病等人体线虫感染 ,证实有广谱、高效、副作用轻的特点。国内 1992年曾有少数病例的临床观察报道[1] 。现经卫生部药政局审批 (批件号为 [98]ＸＬ- 0 7号 ) ,由中山医科大学临床药理基地作
Ivermectin is a new type of drug developed in China. It has been widely used in the treatment of human body nematode infection such as onchocerciasis in foreign countries, confirming the broad spectrum, high efficiency and light side effects. In 1992, there were a few cases of clinical observation reported [1]. Now approved by the Pharmaceutical Administration of the Ministry of Health (approval number [98] XL-0 7), by the Clinical Pharmacology Base of Zhongshan Medical University